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Abstract 
Hippocampal sclerosis is a common acquired disease that is a major cause of drug resistant 
epilepsy. A mechanism that has been proposed to lead from a brain insult to hippocampal 
sclerosis is the excessive generation of reactive oxygen species, and consequent mitochondrial 
failure.  
Here we use a novel strategy to increase endogenous antioxidant defenses by using RTA 408, 
which we show activates nuclear factor erythroid 2-related factor 2 through inhibition of Kelch-
like ECH associated protein 1 (Keap 1) through its primary sensor C151. Activation of nuclear 
factor erythroid 2-related factor 2 with RTA 408 inhibited reactive oxygen species production, 
mitochondrial depolarization and cell death in an in vitro model of seizure-like activity. RTA 
408 given after status epilepticus in vivo increased ATP, prevented neuronal death, and 
dramatically reduced (by 94%) the frequency of late spontaneous seizures for at least four 
months following status epilepticus.  
Thus, acute Keap1 inhibition following status epilepticus exerts a neuroprotective and disease 
modifying effect, supporting the hypothesis that reactive oxygen species generation is a key 
event in the development of epilepsy. 
 
Keywords: Epilepsy, Epileptogenesis, Nrf2-KEAP1 pathway, oxidative stress, mitochondrial 
dysfunction 
 
Abbreviations: ARE = antioxidant response elements; FCCP = carbonylcyanide-p-
trifluoromethoxyphenyl hydrazine; GSH = Glutathione; HEt = dihydroethidium; HS = 
Hippocampal sclerosis; KA = Kainic acid; Keap1 = Kelch-like ECH associated protein 1; MCB 
= Monochlorobimane; NQO1 = NADPH:quinone oxidoreductase; Nrf2 = nuclear factor 
erythroid 2-related factor 2; ROS = reactive oxygen species ; SE = status epilepticus; 
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Introduction 
Epilepsy remains one of the commonest serious neurological diseases, affecting over 50 million 
people worldwide(de Boer et al., 2008). This represents a considerable health care burden not 
just because of the impact of seizures, but also because of the increased morbidities and mortality 
associated with epilepsy. However, the medications that we presently have are designed to target 
the symptom, seizures, rather than modify the disease(Galanopoulou et al., 2012). Many of the 
epilepsies are acquired conditions following an insult to the brain such as a prolonged seizure, 
traumatic brain injury or stroke, and an important challenge is to determine and treat the major 
pathways that lead from the insult to epilepsy (termed epileptogenesis)(Pitkanen and Lukasiuk, 
2011). A number of potential strategies have been identified including targeting inflammation, 
disruption of the blood brain barrier, and gene expression with microRNAs(Vezzani et al., 2011; 
Heinemann et al., 2012; Reschke and Henshall, 2015). However, most of these treatments have 
modest effects or have only been shown to be effective if given during or before the insult 
(substantially lessening their translational potential). 
A common sequela of brain injury is the generation of reactive oxygen species (ROS) and 
induction of oxidative stress. There is growing evidence that inhibiting ROS generation can 
ameliorate neuronal damage in seizures and epilepsy(Kim et al., 2013; Kovac et al., 2014; 
Williams et al., 2015). However, the effects of antioxidant therapy on seizure development have 
been mixed. This may be partly explained by the short-lived neuroprotective effects of direct 
antioxidants, because of their consumption in the process of ROS scavenging. An alternative 
strategy is to increase the endogenous antioxidant defenses of cells by upregulating the 
transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2). Activation of Nrf2 has 
been shown to be protective against oxidative stress in a number of pathologies(Esteras et al., 
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2016). In addition, activation of Nrf2 provides substrates for mitochondria and so increases ATP 
production, which can be protective for cells(Holmstrom et al., 2013; Dinkova-Kostova and 
Abramov, 2015). Nrf2 has been shown to increase in kindled animals and after status epilepticus 
(SE) (Wang et al., 2013), and overexpressing Nrf2 neuroprotects following SE (Mazzuferi et al., 
2013).  
Sulforaphane, a naturally occurring Nrf2 activator, has therefore been proposed as a possible 
disease-modifying treatment in epilepsy(Pauletti et al., 2017). However, sulforaphane is non-
selective, affecting many off-target proteins(Clulow et al., 2017), and can itself exhibit both 
anticonvulsant(Carrasco-Pozo et al., 2015) and proconvulsant  activity(Socala et al., 2017). 
Moreover, sulforaphane is toxic at high dose, and has probable poor penetration of the blood 
brain barrier(Clarke et al., 2011). Together, these may explain why a convincing effect on the 
development of seizures has only been shown when sulforaphane is administered with high dose 
antioxidants(Pauletti et al., 2017).  
In contrast to sulforaphane, cyanoenone triterpenoids are specific for Nrf2(Walsh et al., 2014) 
and 200-400 times more potent than sulforaphane with a much higher therapeutic index(Copple 
et al., 2014). One member of this chemical class, RTA 408, a close structural analog of 
bardoxolone methyl, is a novel Nrf2 activator that has undergone clinical trials in non-small cell 
lung cancer and, in part because of its CNS penetration properties, is now undergoing a clinical 
trial in Friedreich's Ataxia(SHEIKH, 2014). Here we show that RTA 408 activates Nrf2 through 
inhibition of Keap1 through its primary sensor C151. We further observed that RTA 408 inhibits 
ROS production, mitochondrial depolarization and cell death in an in vitro model of seizure-like 
activity. Importantly, our studies demonstrate that, given after SE in vivo, RTA 408 increases 
glutathione and ATP, and prevents neuronal death. Moreover, acute RTA 408 treatment alone 
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results in a dramatic reduction in spontaneous seizures for at least four months following SE. 
Acute inhibition of Keap1 by RTA 408 represents a novel approach to reduce neuronal death and 
modify the development of seizures. 
 
Materials and methods 
Cortical cell cultures 
Mixed cortical neurons and glial cells cultures were prepared from postnatal (P0-P1) Sprague-
Dawley rat pups (UCL breeding colony) according to a modified protocol described by 
Haynes(LW., 1999). The pups were sacrificed by cervical dislocation, and rat brains were 
quickly removed; neocortical tissue was isolated and submerged in ice-cold HBSS (Ca2+, Mg2+-
free, ThermoFisherInvitrogen, Paisley, UK). The tissue was treated with 1% trypsin for 10 
minutes at 37°C to dissociate cells. The final neuronal cell suspension was plated on 25 mm 
round coverslips coated with poly-L-lysine (1 mg/ml, Sigma), and cultured in Neurobasal A 
medium supplemented with B-27 (ThermoFisherInvitrogen) and 2 mM L-glutamine. 
Neocortical cultures were fed once a week and maintained in a humidified atmosphere of 5% 
CO2 and 95% air at 37 °C in a tissue culture incubator. 
The cultures were used for experiments at 13-17 days in vitro (DIV). Neurons were distinguished 
from glia by their typical appearance using phase-contrast imaging. 
 
Recording solutions 
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Preincubations and experiments were performed at room temperature (RT), unless otherwise 
mentioned, and were performed in an HEPES-buffered salt solution (aCSF), composition (in 
mM): 125 NaCl, 2.5 KCl, 2 MgCl2, 1.25 KH2PO4, 2 CaCl2, 30 glucose and 25 HEPES, pH 
adjusted to 7.4 with NaOH.  
Experiments were carried out in the HEPES buffered salt solution including (aCSF) or excluding 
MgCl2 (low-Mg2+) to induce seizure-like activity.  
 
Imaging of intracellular Ca2+ ([Ca2+]c) and mitochondrial membrane potential 
(Δψm) 
Before recording, neocortical neuronal cultures were incubated for 30 minutes with 5 µM Fura-
2-AM (ThermoFisher-Invitrogen, Paisley, UK), and 0.005% pluronic acid in aCSF.  
For simultaneous measurement of [Ca2+]c and Δψm, Rhodamine123 (Rh123) (Sigma, UK) (1 
µM) was added into the culture dishes during the last 15 minutes of the Fura-2-AM loading 
period. Cells were then washed 3 times prior to recordings. [Ca2+]c was expressed by the Fura-2 
ratio. An increase of Rh123 signal indicates depolarization of mitochondria. Rh123 signals were 
normalized to the baseline level (set 0) and maximum signal produced by mitochondrial 
oxidative phosphorylation uncoupling with carbonylcyanide-p-trifluoromethoxyphenyl 
hydrazone (FCCP, 1 µM; set to 100). Cells were then washed 3 times prior to recordings. Seizure 
activity was induced by excluding MgCl2 from the medium. 
Experiments were repeated at 5-7 times with > 3 different cultures. 
 
Imaging of intracellular ROS generation 
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To evaluate rates of ROS production in the cytosol, dihydroethidium (HEt; 5 µM) was present in 
all solutions throughout the experiments. No pre-incubation was used to avoid accumulation of 
oxidized products. Experiments were conducted using 2-3 separate cultures and repeated on 4-6 
coverslips.  
 
Imaging of Glutathione (GSH) 
For GSH measurements, the media was replaced with either aCSF or low-Mg2+ aCSF and cells 
were incubated with 50 µM Monochlorobimane (MCB) (Sigma, St. Louis, MO) for 1 h at room 
temperature. The cells were then washed with aCSF, and images of the fluorescence of the 
MCB-GSH adduct were acquired using a cooled CCD imaging system. Experiments were 
repeated on 9-10 coverslips using > 3 separate cultures. 
 
Neuronal death 
Neurotoxicity was determined following incubation with low-Mg2+ for 2 h at 37 °C, by co-
staining cells with propidium iodide (20 µM) and Hoechst 33342 (4.5 µM) (Sigma, St. Louis, 
MO) in a fluorescent live/dead assay. Experiments were conducted on 3 separate cortical cultures 
and repeated on 9 coverslips for each treatment. In each treated culture coverslip, 5 random 
fields were counted. 
 
Live imaging and analysis 
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Fluorescence images were obtained on an epifluorescence inverted microscope with a 20× 
fluorite objective. Excitation light provided by a xenon arc lamp, the beam passing 
monochromator at 340, 380, 490 or 530 nm (HEt) (Cairn Research, Kent, UK). Emitted 
fluorescence was detected by a cooled CCD camera (Retiga; QImaging). 
 [Ca2+]c and mitochondrial membrane potential were measured in single cells and traces are 
presented as the ratio of excitation at 340 and 380 nm, both with emission at 515 nm. An 
increase of Rhodamine123 signal indicates depolarisation of mitochondria. Rhodamine123 
signals were normalised to the baseline level (set 0) and maximum signal produced by 
mitochondrial oxidative phosphorylation uncoupling with carbonylcyanide-p-
trifluoromethoxyphenyl hydrazone (FCCP, 1 µM; set to 100). Phototoxicity and photobleaching 
of cells was minimized by limiting light exposure to the time of acquisition of the images. 
Fluorescent images were acquired with a frame interval of 10 s. Data were analyzed using Andor 
software (Belfast, UK). 
HEt was excited by illumination at 530 nm. For most of the experiments, we chose to perform 
measurements of ROS production rates with HEt at a single wavelength, first to avoid 
photobleaching and phototoxicity from excitation of cells in the range of UV light. Rates of ROS 
increase were calculated at different time points (2, 10 and 15 min) after exposure to low-Mg2+ 
and were compared with rates recorded during a 1-3 min aCSF exposure period referred to as 
baseline.  
Images of the fluorescence of the MCB-GSH adduct were acquired using a cooled CCD imaging 
system as described using excitation at 380 nm and emission at 400 nm. 
In all the experiments, each culture coverslip represents the average of 70-120 neurons. 
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NQO1 Bioassay 
Hepa1c1c7 murine hepatoma cells were grown in α-MEM supplemented with heat- and 
charcoal-treated 10% (v/v) fetal bovine serum. Mouse embryonic fibroblasts isolated from WT 
or Nrf2-KO mice were grown in in Iscoves Modified Dulbecco's Medium (with L-glutamine), 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 1 x insulin-transferrin-
selenium, and 10 ng/ml epidermal growth factor (Gibco-Invitrogen, Paisley, UK)(Higgins and 
Hayes, 2011). Cultured cells were maintained in a humidified atmosphere at 37oC, 5% CO2. For 
evaluation of the NQO1 inducer activity, cells (104 per well) were grown for 24 h in 96-well 
plates. The medium was then replaced with RTA 408-containing fresh medium, and the cells 
were further grown for either 48 h (Hepa1c1c7) or 24 h (MEFs). There were eight replicates of 
each treatment of eight different concentrations of the inducer. RTA 408 was dissolved in 
acetonitrile, and diluted in the cell culture medium at a ratio of 1:1000. The final acetonitrile 
concentration in the medium was 0.1% (v/v) in all wells. At the end of the treatment period, cell 
lysates were prepared in digitonin and the specific activity of NQO1 was determined using 
menadione as a substrate as described(Fahey et al., 2004).  
 
Generation of stable Keap1-rescued MEF cell lines and Keap1C151S/C151S knock-in 
mice 
All mouse experiments were performed according to the regulations of The Standards for Human 
Care and Use of Laboratory Animals of Tohoku University (Sendai, Japan) and the Guidelines 
for Proper Conduct of Animal Experiments of the Ministry of Education, Culture, Sports, 
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Science, and Technology of Japan. Immortalized Keap1-knockout (KKO) MEF cells were grown 
in low glucose Dulbecco modified Eagle medium (Wako Chemical, Japan) supplemented with 
9% (v/v) fetal bovine serum at 37°C and 5% CO2. The PiggyBac transposon system (PB514B-2; 
System Biosciences, California, USA) was utilized to generate stable cell lines expressing HA-
tagged mouse Keap1 (HA-Keap1) or cysteine mutants of HA-Keap1 as described(Saito et al., 
2015). Keap1C151S/C151S knock-in mice were generated using the CRISPR/Cas9 technology(Saito 
et al., 2015). Thioglycollate-elicited peritoneal macrophages were collected by lavage from 
Keap1C151S/C151S knock-in mice and their WT counterparts. The primary peritoneal macrophage 
cells were grown at 37°C and 5% CO2 in RPMI 1640 medium supplemented with 10% (v/v) fetal 
bovine serum and penicillin-streptomycin (10 U/0.1 mg/ml). 
 
Immunoblotting 
For immunoblotting analysis, cells were grown for 24 h in 6-well plates, and then treated with 
RTA 408 for a further 3 h. Cells were then washed with PBS, and lysed in 200 µl of lysis buffer 
[100 mM Tris-HCl, pH 6.8; 4% (w/v) sodium dodecyl sulfate (SDS); 20% (v/v) glycerol; 
0.001% (w/v) Bromophenol Blue]. The cell lysates were subjected to sonication for 30 seconds, 
and then heated at 95°C for 5 min. After cooling, dithiothreitol (DTT) was added to a final 
concentration of 20 mM, and the lysates were incubated at 37°C for 10 min. Protein 
concentrations were determined by the BCA assay (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA( . Proteins (15-20 µg) were resolved by electrophoresis on an 8% SDS–
polyacrylamide gel, and electrophoretically transferred to a polyvinylidene difluoride (PVDF) 
membrane. After blocking with 10% non-fat milk at room temperature for 1 h, immunoblotting 
was performed with the following antibodies and dilutions: rat monoclonal Nrf2 antibody(Saito 
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et al., 2015) (1:100), rat monoclonal HA antibody (Roche, 3F10, California, USA, 1:1000), rat 
monoclonal Keap1 antibody(Saito et al., 2015) (1:100), and mouse monoclonal α-tubulin 
antibody (Sigma–Aldrich, DM1A, 1:5000-1:10000 dilution). The western blot data are 
representative of three independent experiments. 
 
Animals 
Animal experiments were conducted in accordance with the Animals (Scientific Procedures) Act 
1986, and approved by the local ethics committee. Male Sprague-Dawley rats (Charles River 
Laboratories, UK; 160-180 g) were individually housed with free access to food and water in 12 
h light/dark cycles throughout the study. Animals were acclimatised to the animal house for at 
least 7 days before experimental use. There was no difference in weight between the animals 
randomised to vehicle or RTA 408 (248±8 vs. 257±9 grams, respectively). 
 
Surgery 
Male Sprague–Dawley rats were anaesthetized using isoflurane and placed in a sterotaxic frame 
(Kopf, CA, USA). At the start of surgery, Buprenorphine (0.2 mg/kg; SC) and Metacam (1 
mg/kg; SC) were administered for pain relief. An EEG transmitter (A3028, Open Source 
Instruments)(Chang et al., 2011) was implanted subcutaneously. A subdural intracranial 
recording electrode was positioned above the right hippocampus (2.5 mm lateral and 4 mm 
posterior of bregma(Paxinos G., 1998)), and a reference electrode was implanted in the 
contralateral hemisphere (2.5 mm lateral and 6 mm posterior of bregma). The electrodes were 
fixed to the skull with three skull screws and tissue glue, followed by dental cement. 
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Immediately after surgery, 3-5 ml of warmed Ringer’s solution and Amoxicillin (Betamox LA, 
100 mg/kg) was administered subcutaneously. Rats recovered for 7-10 days before initiation of 
the experiment. Rats were housed separately in Faraday cages and EEG was recorded 
continuously for up to 18 weeks post-surgery.  
 
KA induced SE epilepsy model 
For induction of SE, kainic acid (KA) treatment was used according to a protocol described by 
Hellier et al(Hellier et al., 1998). This model has a low mortality rate and reliably leads to later 
spontaneous recurrent seizures(Williams et al., 2009; Jupp et al., 2012; Liu et al., 2016). Rats 
were injected intraperitoneally with KA (Tocris Bioscience, Bristol, UK) dissolved in sterile 
0.9% saline (10 mg/mL) at a dose of 5 mg/kg. Rats were continuously monitored for convulsive 
motor seizures and for EEG in those rats with implanted transmitters. Hourly KA treatment 
continued in animals without convulsive seizures until class III, IV, or V seizures were evoked 
(scored according to a modified Racine’s scale(Racine, 1972; Ben-Ari, 1985)). Once an animal 
began showing excessive inactivity or excessive activity (i.e. exaggerated running or jumping), 
or had more than 10 class IV/V seizures/h, subsequent injections were delayed or reduced to 2.5 
mg/kg to avoid excessive toxicity and mortality. The endpoint for KA treatment was considered 
either when animals reached class V seizure (i.e. excessive rearing with concomitant forelimb 
clonus and falling) or when the total dose of KA reached 45 mg/kg.  
Animals were included in the study if there was continuous epileptiform activity for 2 h, during 
which spike frequencies were more than 2 Hz, and spike amplitude was at least 3 times 
background. For rats that were not EEG monitored, duration of SE was measured based on 
behavioral manifestation. Start of the status was considered when the rat experienced full motor 
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seizure with loss of postural control and falling. The SE was terminated in all animals at 2 hours 
by intraperitoneal administration of diazepam (5mg/kg ip). All animals were randomized to 
treatment group prior to SE to prevent any bias in length of SE or number of doses of KA. 
 
Drugs administration  
Following 2 h of SE, rats were randomized to treatment with either vehicle (10% DMSO/sterile 
saline) or RTA 408 dissolved in the same vehicle. RTA 408 was synthesized by Reata 
Pharmaceuticals, Inc. In multiple dose experiments, control animals were treated with an 
equivalent volume and number of injections of vehicle as the RTA 408 treated animals. 
 
EEG analysis 
The seizure detection analysis was performed in an automated manner with custom-written 
software to minimize the potential for bias. EEG was processed with the Neuroarchiver tool 
(Open Source Instruments), which determined EEG power for different frequency bands. 
Seizures were characterized by the appearance of high frequency (>2 Hz) with progression of the 
spike frequency, rhythmic spike wave discharges with amplitudes at least three times that of 
baseline EEG (see Fig. 5b) that lasted for a minimum of 10 s. All electrographic seizures were 
confirmed by visual inspection. The majority of seizures were confirmed by video monitoring. 
 
Video monitoring  
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Out of 18 rats recorded for EEG used in this study, 14 rats were simultaneously video monitored 
24 h/d throughout the study with video IP cameras. The time stamps for cameras were 
synchronized to the EEG digitizing computer. Cameras were placed 30-40 cm from each rat. The 
behavioral data were used in this study in cases where EEG seizure activity needed to be 
distinguished from electrical noise generated by movement artifacts.  
 
in vivo Glutathione measurements 
Total (oxidized and reduced forms) Glutathione concentrations were determined by Glutathione 
Assay Kit (Cat No. CS0260, Sigma). The brain tissue was collected from sham rats (Sham, n = 7 
for cortex and n = 6 for hippocampus) and from treated rats 7 days following KA-induced SE for 
2 h, followed by treatment with vehicle (10% DMSO/Saline, KA + vehicle; n = 5), RTA 408 
groups at doses: 17.5 mg/kg once daily for 3 days (KA + RTA 17.5; n = 6), 25mg/kg once daily 
for 3 days (KA + RTA 25; n = 5) and 50mg/kg once daily for 2 days (KA + RTA 50; n = 6). 
Immediately following dissection, tissue was flash frozen by immediate immersion in liquid 
nitrogen.  Tissue (200 mg of lateral part of frontal cortex and 50 mg of dorsal hippocampus) then 
was homogenized in 5 % SSA solution. After centrifuging at 10,000×g for 10 min, 10 µL 
supernatant was used for reaction with 150 µL working mixture (glutathione reductase and 
DTNB solution) at room temperature for 5 min. After that 50 µL nicotinamide adenine 
dinucleotide phosphate (NADPH) solutions were added to initiate the reaction. The glutathione 
content was determined by kinetic measurement with 1 min intervals for 5 min at 412 nm and 
calculated by comparison with standards. For the analysis, investigators were blinded to 
treatment. 
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in vivo ATP measurements 
ATP was measured in rat brain (cortex and hippocampus) using ATP-luciferase-based 
bioluminescence assay kit (Lonza, Basel, Switzerland). The brain tissue was collected from sham 
rats (Sham, n = 6) and from treated rats 7 days following KA-induced SE for 2 h, followed by 
treatment with vehicle (10% DMSO/Saline, KA + vehicle; n = 5), RTA 408 groups at doses: 
17.5 mg/kg once daily for 3 days (KA + RTA 17.5; n = 5), 25mg/kg once daily for 3 days (KA + 
RTA 25; n = 5) and 50mg/kg once daily for 2 days (KA + RTA 50; n = 6). Briefly, immediately 
following dissection, tissue was flash frozen by immediate immersion in liquid nitrogen. Tissue 
(50 mg) was lysed in 500 µl of lysis reagent (for 10 min at room RT) and centrifuged at 10,000 × 
g for 2 minutes to pellet insoluble materials. To 100µl of resulting supernatant, 100 µl of ATP 
monitoring reagent was added in a 96-well plate. After 2 min incubation, luminescence was 
measured using Fluostar Omega microplate reader. ATP standard curve was created, and ATP 
concentration in the tissue lysed from animals was calculated relative to the standard curve, and 
expressed in nmols/g tissue. Analysis was performed blinded to treatment. 
 
Immunohistochemistry 
One week or 15 weeks post KA-induced SE, rats were perfused transcardially under terminal 
anesthesia (Pentobarbital sodium) with heparinized phosphate-buffered saline (PBS; 8 IU/ml), 
followed by 4% paraformaldehyde (PFA) in PBS (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). Brains were removed and left in 4% PFA/PBS overnight at 4°C, and then 
cryoprotected with a 10-20-30% sucrose PBS gradient over 3-4 days until tissue sinks. After 
cryoprotection, brains were embedded in OCT Compound (Sakura Finetek, CA, USA) and 
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stored at -80 °C. For each animal, coronal sections (50 µm) selected from bregma -3.1 to 4 
mm were cut in a cryostat (Leica CM1950) at -20C and fixed on poly-L-lysine coated slides 
(Thermo Fisher Scientific), then left to air dry at RT for 2 h. Brian sections were then circled 
with a water repellent pen (Dako pen; Agilent, CA, USA), permeabilized with PBS, 0.3% 
Triton X-100 for 30 min, blocked with 4% goat serum (Sigma) for 1 h and washed three times 
for 10 min each with PBS. Sections were incubated overnight at 4 °C with a rabbit primary 
antibody against NeuN (1:1000, MAB377, Millipore) in a solution of PBS and 0.3% Triton X-
100. Following three washes with PBS (10 min each), the sections were incubated with Alexa 
fluor-488 goat anti mouse secondary antibody (1:1000; Abcam) for 2 h at RT. The sections 
were washed three times with PBS (10 min each) and mounted with Vectashield and 4',6-
diamidino-2-phenylindole (DAPI) mounting medium (Vector Labs). In some sections, we also 
immunostained for the astrocytic marker glial fibrillary acidic protein (GFAP; Sigma, 1:400) 
followed by secondary antibody (Alexa fluor 594, Invitrogen). Images were obtained at a 
resolution of 1024 × 1024 on Zeiss confocal microscope using 20× objective. Images were 
acquired at 405 nm excitation wavelength and 455nm emission wavelength for DAPI; at 
excitation of 488 nm and emission of 510-613 nm for NeuN; and at excitation of 591 nm and 
emission of 605-652 nm wavelength for GFAP. Image analysis was performed using ImageJ 
software in an automatic cell counting image-based tool, and investigators were blinded to 
treatment. Neurons were identified as NeuN-positive cells with relatively large (>8 µm) soma. 
Cell densities for individual animals represent the average densities of the particular region for 4-
6 brain sections. Results are expressed as neurons (or astrocytes) per mm2.  We quantified 
neuronal damage in the dorsal and ventral hippocampus, and we focused on the hippocampus as 
this is the brain area in which there is the greatest atrophy in this model as measured by 
 17 
 
volumetric MRI(Jupp et al., 2012). The cell counts were performed in the pyramidal cell/dentate 
granule cell layers where the predominant cell types are excitatory neurons. 
 
Statistical analysis.  
Data are expressed as the mean ± SEM. Data were analyzed using unpaired Student’s t test, 
Mann-Whitney U test, one-way ANOVA with Bonferroni post hoc test, or one-way repeated 
measures ANOVA with sequential Bonferroni post hoc test, as appropriate using SPSS 22 
(IBM). The comparison of seizure frequency was analyzed using a generalized log-linear 
mixed model with random effect of animal (autoregressive covariance) and fixed effects of 
treatment group, week, and the interaction between treatment group and week. Sample sizes 
were chosen based on our previous experiences in the calculation of experimental variability. 
The numbers of animals used are described in the corresponding figure legends. 
 
Results 
RTA 408 activates Nrf2 by inhibition of its main negative regulator, Keap1 
Using a Hepa1c1c7 murine hepatoma cell culture, we first tested whether the pentacyclic 
cyanoenone triterpenoid RTA 408 (Fig. 1a) induced the prototypic Nrf2 target enzyme NQO1, 
and demonstrated that it did so with a CD (Concentration that Doubles the specific activity of 
NQO1) of 2.5 nM (Fig. 1b) and that its ability to induce NQO1 was lost in the absence of Nrf2 
(Fig. 1c).  
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Induction of Nrf2 is predominantly triggered by inactivation of Keap1, the mammalian cysteine-
based sensor for electrophiles and oxidants (Dinkova-Kostova et al., 2017). Chemical 
modification(s) of the cysteine sensor(s) of Keap1 inactivate its substrate adaptor function, 
leading to Nrf2 stabilization and subsequent upregulation of Nrf2-dependent transcription. We 
therefore next sought to identify the cysteine sensor(s) within Keap1 for RTA 408(Cleasby et al., 
2014; Huerta et al., 2016).  We used Keap1 knockout (KKO) mouse embryonic fibroblast (MEF) 
cells rescued with N-terminally hemagglutinin (HA)-tagged murine Keap1 ligated to the 
PiggyBac transposon system(Saito et al., 2015). Expression plasmids encoding wild-type (WT) 
or cysteine mutants of three different types (i.e. C151S, C273E/C288W and 
C151S/C273W/C288W) HA-Keap1 were transfected into KKO MEF cells, and stable HA-
Keap1 expressing lines were established.   
 
We found that upon a 3-h exposure to 25 nM or 50 nM RTA 408, Nrf2 is stabilized in the WT 
and in the double mutant C273W/C288E Keap1-rescued KKO MEF cells (WT-KKO MEFs and 
C273W/C288E-KKO MEFs respectively) (Fig. 1d). By contrast, in the single mutant C151S 
Keap1-rescued KKO MEFs (C151S-KKO MEFs) and the triple mutant C151S/C273W/C288W 
Keap1-rescued KKO MEF cells (C151S/C273W/C288W-KKO MEFs), these concentrations of 
RTA 408 were unable to cause stabilization of Nrf2 (Fig. 1d).  Furthermore, we used primary 
peritoneal macrophage cells isolated from WT or Keap1C151S/C151S knock-in mice that were 
generated using the CRISPR/Cas9 technology(Saito et al., 2015). In agreement to the results 
obtained in Fig 1d, exposure of these cells to 15 nM or 30 nM RTA 408 for 3-h led to Nrf2 
stabilization only in the WT, but not in the Keap1C151S/C151S primary peritoneal macrophage cells 
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(Fig. 1e). Taken together, these results establish that C151 in Keap1 is the primary sensor for 
RTA 408. 
 
RTA 408 prevents mitochondrial depolarization without altering calcium 
oscillations during epileptiform activity  
We next determined the functional effect of Keap1 inhibition by RTA 408 in an in vitro model of 
epileptiform activity. We induced epileptiform activity through removal of magnesium from the 
medium; this promotes NMDA receptor activation by vesicular glutamate release and results in 
seizure-like activity and calcium oscillations in neurons(Kovac et al., 2012). The omission of 
magnesium from the solution induced synchronised calcium signals in the control neuronal 
culture (Fig. 2a, n = 70 neurons, 1 experiment (exp.)). Pre-incubation (24 hours) of the cells with 
200 nM RTA 408 did not change the frequency or coastline of low magnesium-induced calcium 
spikes in neuronal culture (Fig. 2 b-d). These data suggest that activation of Nrf2 with 200 nM 
RTA 408 did not change vesicular glutamate release or activation of NMDA receptors in the low 
magnesium model.  
Prolonged seizure-like activity in neurons leads to mitochondrial depolarization, which may be 
the result of a low level of mitochondrial substrates, and/or opening of the mitochondrial 
permeability transition pore(Schuchmann et al., 1999; Kovac et al., 2012). Omission of 
magnesium from the recording medium induced slow and progressive mitochondrial 
depolarization in primary neurons resulting in ~30 % decrease in mitochondrial membrane 
potential (∆ψm) in 30 min (Fig. 2e). Pre-incubation of the cells with 200 nM RTA 408 for 24 
hours protected neurons against a decrease ∆ψm (Fig. 2e). 
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Importantly, incubation of cells with a lower concentration of RTA 408 (50 nM) also effectively 
reduced the effect of low magnesium on mitochondrial membrane potential (Fig. 2e). Thus, 
activation of Nrf2 by incubation with RTA 408 supports mitochondrial metabolism that makes 
neuronal mitochondria less vulnerable to seizure-like activity.  
 
RTA 408 reduces epileptiform activity-induced ROS production and protects 
neurons against oxidative stress and excitotoxicity 
In agreement with previously published studies(Kovac et al., 2014; Williams et al., 2015), we 
found that activation of epileptiform activity by omitting magnesium from the medium induced 
more than a 5-fold increase in the rate of ROS production (n = 403 neurons, 5 exp., Fig. 2f). 
Incubation of co-culture of neurons and astrocytes with 200 nM RTA 408 for 24 hours 
significantly reduced the rate of ROS production in neurons during seizure-like activity 2, 10 and 
15 min after exposure to low-Mg2+ (from 192%, 357% and 564% to 113%, 186 and 291% 
respectively, F(2,12) = 49.415, p < 0.001, Fig. 2f). There was no difference in ROS production 
between RTA 408 pre-treated neurons and low Mg2+ condition at all time points (2 and 10 min: p 
= 1.000; 15 min:  p= 0.107). 
Generation of ROS in brain cells has physiological roles(Angelova and Abramov, 2016) and it 
becomes pathological only when it starts to reduce cellular antioxidants. Epileptiform activity 
significantly decreases the level of the major endogenous antioxidant in the central nervous 
system, glutathione (GSH; Fig. 2g), which indicates oxidative stress. Preincubation (for 24 
hours) of the cortical neurons and astrocytes with 200 nM RTA 408 completely restored the 
GSH pool in cells with seizure-like activity (Fig. 2g).  
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We subsequently determined if this reduction of ROS production translated to a neuroprotective 
effect. Incubation of the cortical primary co-cultures of neurons and astrocytes in low 
magnesium medium for 2 hours induced neuronal loss (32% ± 2.4; Fig. 2h). Activation of Nrf2 
by a 24-h preincubation of the cells with RTA 408 (200 nM) almost completely prevents seizure-
like activity induced neuronal cell death (Fig. 2h).  
 
RTA 408 increases glutathione and ATP and prevents neuronal death following 
status epilepticus in vivo 
We next asked if the antioxidant effects of RTA 408 observed in vitro translate to increased 
glutathione and ATP in vivo. We induced SE using KA, and the animals were randomised to 
either vehicle once a day for three days, or RTA 408 either as three dosing regimens: 17.5 mg/kg 
or 25 mg/kg over three days, or 50 mg/kg for two days. Although glutathione levels drop 
immediately following SE(Cock et al., 2002), we found that in our SE model, they are normal by 
one week (Fig. 3a). However, in the RTA 408 treated SE animals, there was a significant dose-
dependent increase in glutathione to supra-normal levels by one week post-SE (Fig. 3a). This 
was particularly evident in the hippocampus, which at the higher RTA 408 doses demonstrated a 
3-4 fold increase in glutathione levels (Fig. 3a).  Moreover, at one week post-SE, ATP levels 
were reduced in the vehicle treated animals but were restored to supranormal levels in a dose 
dependent fashion by RTA 408 (Fig. 3b). Since 25 mg/kg RTA 408 was well tolerated and 
restored the ATP levels at one week (Fig. 3b), and 50 mg/kg RTA 408 was associated with 
adverse effects (mainly weight loss) in subsequent experiments we used 25mg/kg RTA 408 as 
either a single dose or 3 doses over 3 days. 
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Is this increase in glutathione and protection against ATP depletion associated with 
neuroprotection? KA-induced SE results in significant neuronal damage in the hippocampus that 
can continue to progress for up to 8 weeks(Hopkins et al., 2000; Jupp et al., 2012). We, 
therefore, measured cell densities in the hippocampal subfields of the dorsal hippocampus one 
week and 15 weeks after SE. Significant neuronal loss in the hilus and CA3 is evident at 1 week 
post-SE (Fig. 4c,d) and does not progress by 15 weeks (Fig. 4a,f,g) . This loss was significantly 
ameliorated by RTA 408 (Fig. 4 a,c,d,f,g). There was only a non-significant trend for decreased 
neuronal densities in CA1 at one week (Fig. 4b); however, at 15 weeks there had been 
progressive CA1 neuronal loss, resulting in a significant decrease in neuronal density (p < 0.001 
by unpaired two-tailed Student t-test, Fig. 4a,e). RTA 408 prevented this progressive neuronal 
loss in CA1 in a dose dependent fashion (Fig. 4a,e). We also analysed the effects of RTA408 on 
neuronal and glial damage in the ventral hippocampus at 15 weeks (Supplementary Figure 1) and 
found a similar degree of damage and protective effect in CA1 and CA3 (Supplementary Fig 2). 
 
RTA 408 modifies seizure progression 
Although neuronal loss in the hippocampus is associated with cognitive and neurological deficits 
following SE, decreasing neuronal loss does not necessarily affect the development of 
epilepsy(Khalil et al., 2017). We therefore separately tested if RTA 408 given after SE could 
prevent the development of epilepsy. Animals were randomly assigned to treatment with vehicle 
or RTA 408. Seizures were recorded in 9 animals (per group) for 12 weeks, and in 4 out of 9 
animals in each group recordings were continued to 15 weeks.   
All animals had SE lasting at least 2 hours, terminated with diazepam (5mg/kg ip) (Fig. 5a).  
Following SE, the rats developed spontaneous seizures (Fig. 5b). There was no significant 
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difference between the two groups in terms of total dose of KA (vehicle 16 ± 6 mg/kg, RTA 408 
15 ± 4 mg/kg; p = 0.8) or duration of SE (vehicle 125±15 mins, RTA 408 130±10 mins; p = 0.5). 
For those that developed seizures, there was no significant difference in the latency period 
between SE and the first seizure for the two groups (median delay 13 days, interquartile range 
7.25 days for vehicle treated animals; median delay 17.5 days, interquartile range 18 days for 
RTA 408 treated animals, p = 0.4 Mann-Whitney U test).  In vehicle treated animals, the seizure 
frequency increased up to about 9 weeks (after first spontaneous seizure) and then plateaued. 
Although there was no significant difference in seizure frequency over the first 2 weeks between 
those animals given RTA 408 or vehicle, thereafter the seizure frequency was significantly less 
in those treated with RTA 408 (Fig. 5c,d). From weeks 9-12, there was a 94% reduction in 
median seizure frequency (from 23 to 1 per week, p < 0.01). Those animals treated with RTA 
408 spent 60-80% of days with no seizures compared to 10-30% of days with no seizure for 
those animals that received vehicle (p < 0.05, Fig. 5e,f). There was, however, no difference in the 
distribution of seizure durations between the two groups (Fig. 5g). One out of 9 animals in the 
vehicle treated group did not develop epilepsy. The odds ratio for not developing epilepsy for 
RTA 408 versus vehicle groups was 4 (95% confidence interval 0.3-49), but this did not reach 
significance. 
 
Discussion 
We have thus shown that the cyclic cyanoenone RTA 408 activates Nrf2 through inhibition of 
Keap1. Using an in vitro model of persistent seizure-like activity, we demonstrate that RTA 408 
can prevent mitochondrial depolarization, ROS production, oxidative stress and consequent 
neuronal death. We translated these findings to an in vivo model of prolonged seizure activity, in 
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which we show that RTA 408 increases glutathione levels, increases ATP to supranormal levels, 
and similarly neuroprotects. Importantly, we found that RTA 408 administration has a disease-
modifying effect, dramatically modifying the later development of spontaneous seizures. 
Nrf2 is primarily negatively regulated by Kelch-like ECH associated protein 1 (Keap1)(Itoh et 
al., 1999). Dimeric Keap1 sequesters Nrf2 in the cytoplasm and promotes degradation of Nrf2 
through the ubiquitin-proteasome pathway(Cullinan et al., 2004; Kobayashi et al., 2004; Zhang 
et al., 2004). Electrophiles and oxidants inactivate Keap1 by chemically modifying critical 
cysteine sensors within the protein(Dinkova-Kostova et al., 2002), leading to Nrf2 accumulation 
and increased transcription of Nrf2 target genes(Baird and Dinkova-Kostova, 2011). The 
versatility and relatively long half-lives of the upregulated proteins ensure long-lasting protection 
against many different types of oxidants(Gao et al., 2001). The cyclic cyanoenones are the most 
potent Nrf2 activators known to date(Dinkova-Kostova et al., 2005; Honda et al., 2011). The 
activated Michael acceptor functionality within their structures renders them highly reactive with 
sulfhydryl groups, and they belong to the category of drugs with reversible covalent mode of 
action, a property that makes them suitable for chronic administration(Kostov et al., 2015). 
Although the mechanism of action of RTA 408 had been unclear, we show that it binds to C151 
in Keap1, and so inhibits the interaction of Keap1 with Nrf2, enabling Nrf2 translocation to the 
nucleus(Cleasby et al., 2014; Huerta et al., 2016). In the nucleus, Nrf2 binds to the cis-acting 
antioxidant response elements (ARE), specific promoter sequences in genes encoding phase II 
and antioxidant cytoprotective proteins, including glutathione S-transferase, NADPH:quinone 
oxidoreductase (NQO1), and enzymes involved in the biosynthesis and regeneration of 
glutathione. 
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During prolonged seizures (SE), ROS are produced through activation of NADPH oxidase via 
NMDA receptor activation(Kovac et al., 2014; Williams et al., 2015). ROS and consequent 
peroxynitrite formation can contribute to cell death though lipid peroxidation, inactivation of 
enzymes, mitochondrial permeability transition pore opening (and mitochondrial depolarization) 
and DNA damage(Szabo et al., 2007). Moreover, ROS can directly inhibit mitochondrial 
complex 1 activity, further impeding ATP production(Ryan et al., 2012; Rowley et al., 2015). 
Seizures and seizure-like activity are energy demanding processes with high ATP consumption 
by ion pumps; lower ATP production induced by ROS-induced mitochondrial dysfunction 
rapidly results in energy deprivation and cell death(Kovac et al., 2012). In addition to increasing 
antioxidant cytoprotective proteins, overexpression or activation of Nrf2 can also suppress 
NADPH oxidase activity(Kovac et al., 2015), and so should decrease ROS production and 
accumulation during seizure-like activity. We tested this in an in vitro model of seizure-like 
activity. Importantly, RTA 408 had no direct anti-seizure effect and did not alter the calcium 
dynamics of seizure-like activity, yet RTA 408 decreased ROS production, increased 
glutathione, restored ATP levels and neuroprotected. Thus the protective effect of RTA 408 can 
be explained by stimulation of mitochondrial bioenergetics and reduction of ROS production but 
not through inhibition of the calcium oscillations. However, these protective effects were 
observed in an in vitro model of prolonged seizure-like activity and caution has to be exercised 
in extrapolating this to the in vivo condition.  
We, therefore, asked whether these in vitro results translate to an in vivo effect? To address this, 
we used an established in vivo model of SE, which results in neuronal death in the hippocampus 
in a similar pattern to that observed in human hippocampal sclerosis (the commonest cause of 
drug resistant epilepsy in humans)(Hellier et al., 1998)  and the development of chronic epilepsy. 
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In this model, RTA 408 administration over 3 days increased glutathione levels and rescued ATP 
decreases to supranormal levels by 1 week. This increase in antioxidants and cellular energy 
function resulted in neuroprotection in CA3 and the hilus. In this model, neuronal damage in 
CA1 was not evident until many weeks after the SE and since RTA 408 modified the 
development of epilepsy after 4 weeks, then it is unclear if the later neuroprotection in CA1 is a 
direct effect of RTA 408 or the result of decreasing the later seizure frequency. However, 
evidence in other models seems to indicate that the progression of damage after status epilepticus 
is not solely due to the occurrence of seizures(Pitkanen et al., 2002), and it is also possible that 
the apparent progression that we observed could be due to such processes as the removal of dead 
or dying neurons. In addition, we (as others)(Gualtieri et al., 2012) found evidence of loss of 
astrocytes with chemoconvulsant-induced status epilepticus; in our study, RTA 408 also 
effectively prevented this. 
Acute RTA 408 administration reduced seizure frequency >8 weeks after the SE by > 90%. (at a 
time when RTA 408 would no longer be present) (SHEIKH, 2014). This compares very 
favourably to other disease modifying treatments. Although there was a tendency for there to be 
a greater number of seizure-free animals in the RTA 408 treated group, this did not reach 
significance. An unanswered question is whether longer administration could prevent the 
development of epilepsy altogether. Since the mechanism of action of RTA 408 is through 
modifying gene expression, it is noteworthy that it has a profound effect even when given after 
the epileptogenic insult, markedly increasing the translational potential of this intervention. RTA 
408 is already undergoing clinical trials in other conditions, and the remarkable evidence of 
efficacy presented herein suggests potential for this drug as a disease-modifying treatment in 
epilepsy. 
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Figure legends 
 
Figure 1. RTA 408 increases Nrf2 through inhibition of KEAP1. (a) Chemical structure of 
RTA 408. (b, c) Induction of NQO1 by RTA 408 in Hepa1c1c7 cells (b), and wild-type (WT)and 
Nrf2-knockout MEF cells (c). Cells (104 per well) were grown for 24 h in 96-well plates, and 
subsequently exposed to RTA 408 for 48 h (b) or 24 h (c). There were eight replicates of each 
treatment of eight inducer concentrations. At the end of the treatment period, cell lysates were 
prepared in digitonin and the specific activity of NQO1 was determined using menadione as a 
substrate. Mean values for the eight replicate wells are shown. The standard deviation for each 
data point was within 5% of the value. (d, e) Western blot analyses of total cell lysates of Keap1-
knockout MEF cells rescued with either WT, single cysteine mutant C151S, double cysteine 
mutant C273W/C288E, or triple cysteine mutant C151S/C273W/C288E of mouse N-terminally 
tagged HA-Keap1 (d) or primary peritoneal macrophages isolated from WT or Keap1C151S/C151S 
knock-in mice (e). Cells grown for 24 h in 6-well plates were exposed to vehicle (0.1% DMSO) 
or RTA 408 for a further 3 h, after which the cells were lysed. Immunoblotting was performed 
on whole cell lysates using antibodies against Nrf2, HA, Keap1 and α-tubulin. 
 
Figure 2. RTA 408 decreases ROS production, and prevents mitochondrial membrane 
depolarization and neuronal death during seizure-like activity in cortical neurons.  
Synchronous Ca2+ oscillatory indicates seizure-like activity in neurons induced by replacement of 
aCSF with low-Mg2+ aCSF in control (a, n = 70 neurons, 1 experiment (exp.)) and in RTA 408 
(200 nM, 24 h) treated culture (b, n = 72 neurons, 1 exp.). RTA 408 changed neither the 
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frequency (c, t(11) = 1.644, p = 0.129, n = 627 neurons from 7 exp. for low Mg2+; n = 536 
neurons from 6 exp. for RTA 408 (200 nM, 24 h)) nor the coastline (d, t(11) = 2.245, p=0.811) 
of Ca2+ oscillations. (e) Left panel: Representative traces of mitochondrial membrane potential 
(Δψm) in neurons (mean ± SEM) in aCSF (black line; n=112 neurons, 1 exp.), low-Mg2+ (red; 
n=120 neurons, 1 exp.) and neurons exposed to low magnesium preincubated with RTA 408 
(200 nM) for 24 h (blue; n=106 neurons, 1 exp.). FCCP (1 µM; set to 100%) was added to 
cultures at the end of each experiment. Arrow indicates replacement of aCSF with low-Mg2+ 
aCSF. Right panel: bar chart showing normalized Rhodamine123 fluorescence of neurons in 
aCSF (n = 559 neurons, n=6 exp.) during low-Mg2+ treatment (n=627 neurons, 7 exp), RTA 408 
preincubated cultures with 50 nM for 24 h (n = 410 neurons, 5 exp.) and for 48 h (n = 416 
neurons, 5 exp.) and with 200nM for 24 h (n = 536 neurons, 6 exp.), at different time points 
following exposure low-Mg2+. (f) Left panel:  Representative experiments of neuronal HEt 
fluorescence measurements in aCSF (black, n=91 neurons, 1 exp.), low-Mg2+ condition (red line, 
n=88 neurons, 1 CS), and in neurons exposed to low-Mg2+ preincubated with RTA 408 (200 nM, 
24 h) (blue line, n = 96 neurons, 1 exp.). Right panel: bar chart summarizing the rates (mean ± 
SEM) of ROS production at 2, 10 and 15 minutes in aCSF (n = 353 neurons, 4 exp.), after 
omission of Mg2+ from the extracellular solution (low-Mg2+; n =4 03 neurons, 5 exp.,) and RTA 
408 treated neurons in low-Mg2+ condition (n = 496 neurons, 6 exp.). (e-f) Data were analyzed 
by repeated measures one-way ANOVA (e: F(4,24) = 26.689, p < 0.001; f: F(2,12) = 49.415, p < 
0.001) followed by Bonferroni post hoc tests. **p < 0.01, *** p< 0.001 relative to low-Mg2+ 
condition. (g) Low-Mg2+ (n = 9 exp.) treatment significantly decreases the level of GSH 
(measured using MCB fluorescence) compared to aCSF (n = 10 exp.) and RTA 408 (200 nM, 24 
h) pretreated cultures (n = 10 exp.). (h) Percentage of dead neurons in cultures exposed to low-
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Mg2+ (n = 9 exp.) is significantly higher when compared with exposure to aCSF (2 h; n = 9 exp.) 
and RTA 408 (200 nM, 24 h) preincubated cultures exposed to low-Mg2+ (2 h; n=9 exp.). (g-h) 
Data were analyzed by one-way ANOVA (g: F(2,26) = 12.425,  p< 0.001; h: F(2,24) = 22.100,  p 
< 0.001) with Bonferroni post hoc test **p < 0.01, *** p < 0.001 relative to low-Mg2+ condition. 
 
Figure 3. RTA 408 rescues total glutathione (GSH) and ATP levels following KA-induces 
SE in vivo. (a) Total (oxidized and reduced forms of GSH) were measured in the cortex and 
hippocampus of sham rats (Sham; n = 7 for cortex and n = 6 for hippocampus), and from treated 
rats 7 days following KA-induced SE (2 h), followed by vehicle (10% DMSO/Saline KA + 
vehicle; n = 5), RTA 408 groups at doses: 17.5 mg/kg once daily for 3 days (KA + RTA 17.5; n 
= 6), 25mg/kg once daily for 3 days (KA + RTA 25; n = 5) and 50mg/kg once daily for 2 days 
(KA + RTA 50; n = 6). (b) ATP levels measured in the same animals (Sham; n = 6), vehicle (KA 
+ vehicle; n = 5), RTA 408 17.5 mg/kg once daily for 3 days (KA + RTA 17.5; n = 5), RTA 408 
25 mg/kg once daily for 3 days (KA + RTA 25; n = 5) and RTA 408 50 mg/kg once daily for 2 
days (KA + RTA 50; n= 6). 
Data are expressed as mean±SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 versus KA group, by 
one-way ANOVA with Bonferroni post hoc test. In a, cortex: F(4,24) = 18.197, p < 0.001; 
Hippocampus : F(4,22) = 101.409, p < 0.001; In b, cortex: F(4,21) = 11.738, p < 0.001; 
Hippocampus: F(4,21) = 20.262, p < 0.001. 
 
Figure 4. RTA 408 prevents neuronal cell death following KA-induced SE in rats. (a) 
Representative images for CA1, CA3 and hilus of coronal sections from vehicle (10% 
DMSO/Saline) treated and RTA 408 treated rats 15 weeks after SE; scale bar = 100 µM. (b-g) 
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Cell densities in CA1, CA3 and hilus of sham (n=6), and vehicle (n = 5) and RTA 408 (25 
mg/kg/day for 3 days; n = 5) treated rats 1 week (b-d) and 15 weeks (e-g); in sham (n = 6), 
vehicle (n = 7), RTA 408 (25 mg/kg/day for 1 day; n = 5) and RTA 408 (25 mg/kg/day for 3 
days; n = 7)  following 2 h KA induced SE. Data are expressed as mean ± SEM numbers of 
animals. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to vehicle group by one-way 
ANOVA followed by Bonferroni post hoc test. b: F(2,13) = 2.806, p = 0.097; c: F(2,13) = 9.220, 
p = 0.003; d: F(2,13) = 42.138, p < 0.001; e: F(2,13) = 20.536, p < 0.001; f: F(2,13) = 10.236, p 
< 0.001; g: F(2,13) = 24.550, p < 0.001. 
 
  
Figure 5. RTA 408 modifies seizure progression. (a) EEG sample traces recorded for status 
epilepticus (SE): An asterisk indicates the beginning of SE whereas an arrow indicates 
termination with Diazepam. (b) Typical EEG example of a spontaneous seizure post SE, 
expanded in the right panel. Note the rhythmical high frequency discharges at the beginning of 
the seizure (2) when compared to baseline (1). This rhythmic fast activity increases in amplitude 
(3) and decreases in frequency (4) towards the end of the seizure thus fulfilling the criteria for 
EEG seizure activity. (c-d) Bar charts of mean frequency (± SEM) of electrographically recorded 
seizures following KA induced SE for control rats, treated with vehicle (10% DMSO/Saline) 
once daily for 3 days (n = 9) and RTA 408 treated rats (RTA 408 25 mg/kg once daily for 3 
days; n = 9) 1-12 weeks (c; F(1,192) = 5.828, p < 0.05) and 13-15 weeks following the first 
spontaneous seizure (d; F(1,18) = 10.163, p < 0.01); Animal numbers in d: n = 4 for both groups. 
* p < 0.05, ** p < 0.01 and *** p < 0.001 by generalized log-linear mixed model followed by 
sequential Bonferroni post hoc test. (e) Probability distribution illustrating the probability of 0-10 
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seizures/day for each individual vehicle (n = 9) and RTA 408 treated rat (n = 9). (f) Bar chart 
summarizing mean ± SEM seizure probability across time ** p < 0.01 probabilities of seizure 
free days were compared using Mann-Whitney U. (g) Seizure duration distribution for the same 
animals as in panel c, demonstrating no significant difference between vehicle or RTA408 
treated animals. 
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Supplementary Figure 1. Immunohistochemical analyses of the rat ventral hippocampus 15 weeks after 
SE. (A) Coronal section of the rat ventral hippocampus immunostained for a neuronal marker (NeuN), 
the astrocytic marker glial fibrillary acidic protein (GFAP) and DAPI in RTA 408 treated rat. (B) 
Representative images for immunostaining in the CA1 and CA3 regions of the hippocampus of rats 
treated with vehicle or RTA 408 (25 mg/kg) for 3 days after KA induced SE.   
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Supplementary Figure 2. Neuronal and astrocytic cell densities in CA1 and CA3 of the rat ventral 
hippocampus 15 weeks after SE. Neuronal cell densities in CA1 (A) and CA3 (B) and astrocytic cell density 
of CA1 (C) and CA3 (D) (of the same areas analysed in A and B, respectively) of sham (black, n=5), and 
vehicle (red, n=5) and RTA 408 (25 mg/kg/day for 3 days; blue, n = 5) treated rats 15 week following 2 h 
KA induced SE. Data are expressed as mean±SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to 
sham group by one-way ANOVA followed by Tukey’s post hoc test.  
 
 
